BIOMAT Database Logo BIOMAT Database Logo

Baseline E138 reverse transcriptase resistance-associated mutations in antiretroviral-naive HIV-infected patients. 2012

Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti

UI MeSH Term Description Entries
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068696 Rilpivirine A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone. R278474,Rilpivirine HCl,Rilpivirine Hydrochloride,TMC 278,TMC-278,TMC278,278, TMC,HCl, Rilpivirine,Hydrochloride, Rilpivirine
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.
February 2023, AIDS research and human retroviruses,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia.
March 2013, Journal of acquired immune deficiency syndromes (1999),
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients.
July 1999, AIDS (London, England),
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women.
February 2003, Journal of acquired immune deficiency syndromes (1999),
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
[Antiretroviral therapy with three nucleoside reverse transcriptase inhibitors in treatment-naive HIV-infected patients in Abidjan (Cote d'Ivoire)].
January 2012, Medecine et sante tropicales,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
November 2006, Archives of medical research,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
January 2012, Antiviral therapy,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Short communication: Drug resistance mutations in the HIV type 1 protease and reverse transcriptase genes in antiretroviral-naive Vietnamese children.
October 2012, AIDS research and human retroviruses,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans.
January 2011, East African medical journal,
Marc O Siegel, and Matthew Swierzbinski, and Virginia L Kan, and David M Parenti
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
April 2006, The new microbiologica,
Copied contents to your clipboard!